|
|
News Breaks | | | | October 31, 2012 | | 08:14 EDT |  | ISIS | Isis Pharmaceuticals reports positive interim Phase 1 data on ISIS-STAT3Rx
Isis Pharmaceuticals announced that preliminary data from the Phase 1 study of ISIS-STAT3Rx in patients with cancer were presented today at the Oligonucleotide Therapeutics Society in Boston. Interim results of the initial dose escalation study in patients with cancer showed that ISIS-STAT3Rx treatment resulted in clear responses in patients with advanced cancer who were refractory to prior chemotherapy treatment, with an acceptable safety profile. Based on these results, Isis has initiated a Phase 2 study in focused patient populations with advanced cancer. | |
|
News For ISIS From The Last 14 Days Check below for free stories on ISIS the last two weeks. |
|
|
| May 20, 2013 | | 07:34 EDT |  | ISIS | UBS to host a conference
 Subscribe for More Information | |
|
|
|
|
|
|
